Prevalence and risk factors for HBV and HCV in prisoners in Iran: a national bio‐behavioural surveillance survey in 2015

• DOI: 10.1111/tmi.13065
• Publication Date: 2018-04-26T19:01:50Z
• Authors: Ghobad Moradi; Mohammad‐Mehdi Gouya; Fatemeh Azimizan ...; Amjad Mohamadi Bo...; Sonia Darvishi; Mohammad Reza Agh...; Mahmood Nabavi; Ramin Alasvand; Mehrzad Tashakorian; Bijan Nouri; Khaled Rahmani; Leila Molaei
• Keywords: Hepatitis C; Hepatitis B

Summary Objectives To provide more accurate estimates of the prevalence Hepatitis B (HBV) and C (HCV) their contributing factors among prisoners in Iran. Methods Cross‐sectional study 6200 Iranian 2015. Data were collected through questionnaires interviews. HBV infection HCV exposure status participants was determined by HBsAg antibodies blood tests using enzyme‐linked immunosorbent assay (ELISA). analysed STATA‐12. Result Prevalence 9.48% (95% CI: 8.73–10.27), 2.48% 2.07–2.89) general prison population. In multivariate analysis, most important risk factor for a history drug use lifetime (adjusted odds ratio, AOR: 1.8, 95% 1.17–3.02). The main (AOR: 4.08, 2.56–6.27), age over 30 2.68, 2.01–3.56), having tattoos (AOR = 1.67, 1.35–2.07). Conclusion Although vaccination is used to control prisoners, alarming population Iran, especially people who inject drugs. Eliminating viral hepatitis Iran 2030 requires national commitment rapid measures targeting this high‐risk group. Given increased efficiency treatment recent years, prisons an opportunity access patients treatment.